Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Creative Drug Pricing Hindered By Medicaid Best Price, Stakeholders Say

This article was originally published in The Pink Sheet Daily

Executive Summary

Requirement that drug manufacturers pay Medicaid rebates based on the best price available to any purchaser impedes payer efforts to negotiate value-based pricing for costly drugs, Pfizer and Express Scripts say.


Related Content

CMS Wants To Facilitate Value-Based Discounts For HCV Drugs In Medicaid
HHS Raises Profile In Drug Costs Discussion
Melanoma Approvals Break New Ground In Immunotherapy
Bristol Offers Yervoy For Free In New Early Melanoma Indication
Express Scripts: HCV Formulary Could Change With Merck Combo's Approval


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst